EIF5A and ischemic disease: To reinforce this point of view, recent data support the fact that short, punctual and reversible inhibition of eIF5A hypusination is highly relevant in the main ischemic injuries such as transplantation and stroke and that this breakthrough should open up a new pharmacological strategy for ischemic diseases.